Safety of concurrent administration of dexrazoxane and doxorubicin in the canine cancer patient∗

W. M. FitzPatrick, N. G. Dervisis and B. E. Kitchell

Department of Small Animal Clinical Sciences, College of Veterinary Medicine, Michigan State University, East Lansing, MI, USA

Abstract
Doxorubicin may cause a rare but serious cardiotoxicity. Dexrazoxane is a cardioprotectant drug used to reduce the risk of cardiotoxicity in human patients. In this study, 25 tumour-bearing dogs were treated with concurrent doxorubicin and dexrazoxane. The total number of doses of dexrazoxane given was 54 (range 1–5 doses per dog, median 2 doses). Five dogs received more than 165 mg m² cumulative doxorubicin dose before starting dexrazoxane. Haematologic, gastrointestinal and cardiovascular toxicities were considered tolerable. The combination of doxorubicin with dexrazoxane was well tolerated with minimal side-effects in this patient cohort. Future studies are required to evaluate potential cardioprotective effects of dexrazoxane given concurrently with doxorubicin.

Introduction
Doxorubicin is an anthracycline antibiotic agent that acts as a topoisomerase II inhibitor. This classical cytotoxic agent has been a mainstay of medical oncology for more than 40 years and is used for the treatment of a wide variety of human malignancies. In canine cancer patients, doxorubicin is used to treat a similar array of tumours including lymphomas, soft-tissue sarcomas, osteosarcomas and histiocytic diseases, among other indications. Repeated administration of doxorubicin can result in a dose-dependent potentially irreversible cardiomyopathy.1 Doxorubicin’s chemotherapeutic effects are mediated by several complex biomolecular events.2 Suggested mechanisms of cytotoxicity include intercalation into DNA leading to inhibition of macromolecule synthesis; generation of reactive oxygen species (ROS) leading to DNA damage or lipid peroxidation; DNA binding, alkylation or cross-linking; interference with DNA unwinding or DNA strand separation and helicase activity; direct membrane effects; initiation of DNA damage via inhibition of topoisomerase II and apoptosis in response to topoisomerase II inhibition.3,4 Drugs that inhibit topoisomerase II can be classified as being either catalytic inhibitors or DNA cleavage drugs, depending on where the site of enzyme action occurs in the catalytic cycle.5,6 Doxorubicin’s DNA cleavage-enhancing effect stabilizes the DNA–enzyme complex in its cleaved conformation, which inhibits resealing and leads to DNA double-strand breaks and cell death.3,4,7–10

In human patients, retrospective studies have identified risk factors for increased anthracycline-induced chronic cardiomyopathy.11,12 Examples of risk factors include age greater than 70 years, ionizing radiation to the chest wall, pre-existing cardiac disease and co-administration of other cytotoxic agents such as cyclophosphamide and paclitaxel.11 Pre-existing cardiac risk factors for developing
cardiotoxicity include active congestive heart failure (CHF), history of myocardial infarction within the preceding year, hypertension, aortic stenosis, diabetes mellitus and previous anthracycline administration. Children especially appear to be at increased risk for doxorubicin cardiotoxicity. The progression of cardiomyopathy in human patients is variable. Risk factors for doxorubicin cardiotoxicity in the dog have not been fully elucidated. One factor that has been shown to be a risk for the development of CHF in the dog is body weight. However, history of pre-existent cardiac disease, cumulative doxorubicin dose exceeding 240 mg m\(^{-2}\), as well as other aetiologies may confer risk similar to that reported for human cancer patients.

At the molecular level, doxorubicin-induced cardiotoxicity is variably attributed to several different mechanisms. The primary mechanism for cardiotoxicity is thought to derive from the generation of ROS by doxorubicin. This ROS production is catalysed by the complexing of doxorubicin with iron. The quinone groups on the B ring of the anthracene structure are reduced, leading to the production of doxorubicinol. Interaction of doxorubicinol with oxygen yields oxygen free radicals. The semiquinone reacts with hydrogen peroxide producing a hydroxyl radical in the tissues. These subsequent reactions can occur in the presence or absence of iron. Free radicals can result in damage at different intracellular sites such as the nuclear envelope, cell membrane, mitochondria, DNA and sarcoplasmic reticulum. In the cardiac myocyte in particular, damage to the sarcoplasmic reticulum results in a decrease in bound calcium. Contractility is decreased by the effects of low bound calcium on the actin–myosin complex. Free Ca\(^{2+}\) can also activate proteases within the myocardium, consequently damaging myofibrils. Another proposed mechanism of myocardial damage associated with doxorubicin is thought to be altered levels of cellular free radical scavenging enzymes including superoxide dismutase (SOD), catalase and glutathione peroxidase. After doxorubicin exposure, myocardial levels of glutathione peroxidase decrease while SOD level is unaffected. It should be noted that in some mammalian systems, cardiac myocytes have low catalase levels compared with the amount of this enzyme seen in other organs. Cardioprotective agents such as dexrazoxane mitigate cardiac myocyte damage caused by doxorubicin but not damage induced by the related anthracenedione derivative mitoxantrone. This finding suggests possible unexplained mechanisms for chemotherapy-induced damage induced by anthracyclines.

More recently, it has been postulated that the mitochondria is the primary target of doxorubicin-induced oxidative stress. Doxorubicin has been shown to induce heart-specific mutations and quantitative defects in mitochondrial DNA (mtDNA). This results in a cardiac impairment of mtDNA-encoded respiratory chain subunits and dysfunction of the respiratory chain, promoting ROS release. Therefore, it is believed that somatically acquired mtDNA lesions play an essential role in the doxorubicin’s ‘dose memory’, leading to the clinical onset of cardiomyopathy with lifelong cumulative doxorubicin dosing.

In addition, oxidative stress is a primary mechanism of doxorubicin cardiotoxicity resulting in increased ROS liberation, lipid peroxidation and decreased levels of antioxidants and sulphhydryl groups. There are many other potential contributory mechanisms that have been postulated for doxorubicin-induced cardiomyopathy. Table 1 illustrates the many proposed mechanisms of doxorubicin cardiotoxicity, which are reviewed by Takemura and Fujiwara.

Dexrazoxane is a bisdioxopiperazine used to protect against doxorubicin-induced cardiotoxicity. Dexrazoxane has been approved by the Food and Drug Administration to decrease myocardial toxicity of doxorubicin in human patients with metastatic breast cancer receiving a cumulative doxorubicin dose greater than 300 mg m\(^{-2}\) and was more recently approved for treatment of anthracycline extravasation. Initially, dexrazoxane was evaluated for anti-cancer properties, but the drug was found to have limited activity as a cytotoxic agent. The cardioprotective mechanism was traditionally believed to be related to the iron-chelating
Table 1. Proposed mechanisms of doxorubicin-induced cardiotoxicity

<table>
<thead>
<tr>
<th>Mechanism</th>
</tr>
</thead>
<tbody>
<tr>
<td>Generation of reactive oxygen species</td>
</tr>
<tr>
<td>Damage to nuclear envelope, cell membrane, mitochondria, DNA and sarcoplasmic reticulum</td>
</tr>
<tr>
<td>Altered levels of free radical scavengers</td>
</tr>
<tr>
<td>Inhibition of nucleic acid and protein synthesis</td>
</tr>
<tr>
<td>Release of vasoactive amines (histamines, catecholamines and prostaglandins)</td>
</tr>
<tr>
<td>Alteration of adrenergic function and adenylate cyclase activity</td>
</tr>
<tr>
<td>Mitochondrial abnormalities</td>
</tr>
<tr>
<td>Lysosomal changes</td>
</tr>
<tr>
<td>Modification of sarcolemmal Ca$^{2+}$ transport</td>
</tr>
<tr>
<td>Alteration of Na$^{+}$-K$^{+}$ ATPase and Ca$^{2+}$-ATPase activities</td>
</tr>
<tr>
<td>Imbalance in myocardial electrolytes</td>
</tr>
<tr>
<td>Impairment of the membrane binding, assembly and enzymatic activity of mitochondrial creatinine kinase</td>
</tr>
<tr>
<td>Induction of nitric oxide synthase, leading to nitric oxide and peroxynitrite production and nitration/inactivation of myofibrillar creatine kinase and/or metalloproteinases</td>
</tr>
<tr>
<td>Reduction of expression of cardiac-specific genes, possibly by affecting expression and function of dox-sensitive transcriptional regulatory proteins</td>
</tr>
<tr>
<td>Induction of apoptosis in vascular cells and cardiac myocytes, demonstrated by caspase activation and internucleosomal DNA degradation</td>
</tr>
</tbody>
</table>

properties of the ring-opened metabolite of dexrazoxane, ADR-925. The ring-closed form of the parent compound is an effective topoisomerase II catalytic inhibitor that stabilizes the DNA–enzyme complex in a ‘closed clamp’ conformation. This results in the enzyme being less sensitive to cleavage enhancers. As a result, dexrazoxane inhibits enzymatic activity without causing DNA strand breaks. More recently, there have been a preponderance of studies suggesting other mechanisms of cardioprotection of dexrazoxane. Examples include blocking apoptosis in ventricular myocytes and identifying that daunorubicin-induced apoptosis may involve downstream products of superoxide which can be blocked by chelators and SOD. Additionally, selective cardiotoxicity may be demonstrated in rat embryonic cardiomyocytes but not adult cardiomyocytes. This has been illustrated by showing that the apoptotic pathway is more active in immature cardiac cells than in adult cardiac cells. Furthermore, the contribution of the cytochrome c-Apaf 1-caspase-9 pathway to doxorubicin cardiotoxicity may be limited in the adult myocardium. This may in part explain the increased incidence of developing dilative cardiomyopathy and chronic heart problems in children exposed to anthracyclines. It is noteworthy to consider that the same may be true in our canine patients. In addition, work by Lyu et al. revealed that dexrazoxane can antagonize the formation of Top2α and Top2β cleavage complexes. Dexrazoxane can also induce specific degradation of the Top2β isozyme which is present in the hearts of adult mice, while Top2α is not. Consequently, Lyu et al. postulate two possible mechanisms that explain the cardioprotective effects of dexrazoxane as regards doxorubicin-induced DNA damage. These proposed mechanisms are direct interference with formation of the Top2 cleavage complexes and Top2β downregulation via proteasomal degradation.

Dexrazoxane was evaluated in preclinical dog studies that demonstrated its safety when administered to normal dogs and in conjunction with doxorubicin. To date there are no published studies evaluating the safety or cardioprotective effects of dexrazoxane in clinical canine cancer patients that have received doxorubicin.

In this report, we describe our experience with the use of dexrazoxane in dogs treated with doxorubicin (dox/dex) for a variety of neoplastic diseases. Our hypothesis is that dexrazoxane can be safely administered to canine cancer patients in conjunction with doxorubicin.

Materials and methods

For inclusion in this study, dogs had to meet at least one of the following criteria: pre-existing diagnosed clinical heart disease; onset of impaired systolic...
function during the course of doxorubicin therapy; cumulative dose of doxorubicin of 180 mg m⁻² or cardiac disease as determined by echocardiographic evaluation. Dogs were not included specifically for subclinical valvular insufficiency in the absence of one of the aforementioned cardiac concerns.

Evaluated parameters included the following: fractional shortening (FS), fractional area (FA), left ventricular area during systole and diastole, left ventricular internal dimension during systole and diastole. Echocardiographic criteria for defining significant cardiac impairment (systolic dysfunction) included having a FA less than 40% and/or FS less than 25%. For standardization purposes, the serial echocardiography data were re-evaluated by a single cardiologist. The baseline echocardiogram was defined as the study conducted before the first dose of dexrazoxane, regardless of prior doxorubicin exposure. The comparator echocardiogram was the final echocardiogram performed for each patient. Statistical evaluation of cardiac function status between these time points was analysed by the paired Student’s t-test using standard software (PASW-Statistics 17, 2009; SPSS, Chicago, IL, USA).

Drug administration

Dexrazoxane was administered for 5–10 min as an intravenous (IV) infusion to patients at a level of 10 times the administered milligram dose of doxorubicin, 10 min before the chemotherapy agent was given. Doxorubicin was administered IV in 0.9% NaCl for 25 min at a dose of 1 mg/kg for patients weighing less than 10 kg and 30 mg m⁻² for patients weighing more than 10 kg.

Patients were serially evaluated by means of physical examination, echocardiography, electrocardiography, complete blood counts, serum biochemistry panels and urinalyses. Neoplastic disease status was re-assessed by means of caliper measurements of enlarged peripheral lymph nodes, thoracic radiographs and abdominal ultrasonography. Additional clinical data collected included follow-up for survival duration, cause of death and determination of any cardiac, haematologic and gastrointestinal toxicities [assessed by Veterinary Cooperative Oncology Group (VCOG) toxicity scores].

Results

Twenty-five client-owned tumour-bearing dogs were included in this retrospective study. Dogs received dexrazoxane concurrently with doxorubicin during the study period, which extended from January 2003 to December 2008 at the Veterinary Teaching Hospital of Michigan State University (MSU). Patient demographics included 9 neutered males, 3 intact males, 12 spayed females and 1 intact female. Breeds represented included five Golden Retrievers, three mixed breed dogs, three Rottweilers, two Labrador Retrievers, two Shi Tzus, two Boxers and one each of the following breeds: German Shepherd, Havenerse, English Terrier, Borzoi, Chesapeake Bay Retriever, English Springer Spaniel, Shetland Sheepdog and Siberian Husky. Ages of the dogs in this study population ranged from 4 to 12 years, with a mean age of 8 years. Weights ranged from 4.9 to 50 kg; doxorubicin dose was calculated based on the estimation of lean body weight. Four of the dogs had pre-existing heart disease and one had uncontrolled hypertension at the time of inclusion in the study. Two Golden Retrievers had mitral regurgitation coupled with decreased systolic function on echocardiogram, one Boxer had tricuspid valvular insufficiency and frequent unifocal ventricular premature contractions (VPCs) and one Shi Tzu had both mitral and tricuspid insufficiency with left atrial enlargement. The cancers treated in these 25 dogs included 15 lymphomas, 7 osteosarcomas and 1 each of fibrosarcoma, haemangiosarcoma and carcinoma.

The total number of doses of dexrazoxane given was 54 (range 1–5 per dog; median 2). The cumulative doxorubicin dose received before the first dose of dexrazoxane was administered ranged from 0 to 180 mg m⁻². Five dogs received more than 165 mg m⁻² cumulative doxorubicin dose before starting dexrazoxane. The median cumulative doxorubicin dose administered with dexrazoxane was 105 mg/m² (range 30–270 mg/m²). One dog received a single dose of dexrazoxane to counteract a suspected minimal volume of doxorubicin extravasation; this patient was excluded from the cardiac analysis.

Haematologic, gastrointestinal and cardiovascular toxicities were assessed using the published
VCOG criteria. There were 35 episodes of haematologic toxicity noted during the 54 doses of dox/dex administered in the course of this study. Aneamias ranged from Grade 1 (13 of 54, 24%) to Grade 2 (7 of 54, 12.9%), while neutropenia was observed to encompass Grade 1 (8 of 54, 14.8%), Grade 2 (1 of 54, 1.8%), Grade 3 (1 of 54, 1.8%) and Grade 4 (2 of 54, 3.7%). Thrombocytopenias were seen at the toxicity level of Grade 1 (7 of 54, 12.9%) and Grade 2 (1 of 54, 1.8%). Gastrointestinal toxicity events were observed in 10 patients through the course of our study. Gastrointestinal toxicities were reported to be emesis of Grades 1 (6 of 54, 11.1%) and 2 (3 of 54, 5.5%), and Grade 1 diarrhoea (9 of 54, 16.6%).

Of the seven dogs with serial echocardiographic studies available for review, no statistically significant changes were noted for any of the aforementioned cardiac parameters. There was no statistically significant evidence of decline in systolic function after administration of dox/dex.

Treatment was stopped for three dogs because of the attending oncologists’ assessment of progressive heart disease during the course of the study. One Shi Tzu with severe mitral regurgitation, mild tricuspid regurgitation and increased left atrial size went on to develop clinical signs of CHF. At the time CHF was suspected, this patient was discovered to have aspiration pneumonia. The dog subsequently succumbed to sepsis and multi-organ failure. This aspiration event occurred 3 weeks after the eight dose of doxorubicin (one dexrazoxane dose was co-administered with the final dose of doxorubicin). One Boxer with moderate tricuspid regurgitation but without heart failure had occasional VPCs. The attending oncology clinician elected to discontinue doxorubicin because of the enlargement of the right atrium on thoracic radiographs, but progressive heart disease was not corroborated by echocardiographic assessment. The final dog was an English Terrier that had moderate mitral regurgitation at initiation of therapy, with subsequent decrement in systolic function (FS decreased from 20.2 to 18.8%). The clinician elected to discontinue treatment primarily because of owner’s concern for gastrointestinal toxicity and also concern for cardiac toxicity based on a cardiologist’s assessment of increased risk for cardiotoxicity with additional doxorubicin administration. For two of these three dogs for whom serial echocardiographic evaluation was performed, no statistical change in echocardiographic values was detected. The remaining 22 dogs discontinued the dox/dex protocol because of tumour progression. No deaths specifically attributable to heart disease were observed in this patient cohort.

Discussion

To the authors’ knowledge, this is the first report evaluating the safety of dexrazoxane in the clinical setting in the canine patient. In this admittedly limited study, dexrazoxane appeared to be well tolerated. We found the rates of gastrointestinal and haematologic toxicity of dox/dex in the present study to be comparable to those reported in the historical veterinary literature for doxorubicin alone. In one study by Mutsaers et al., the incidence of severe gastrointestinal toxicities from single-agent doxorubicin used to treat canine lymphoma was 17%. Postorino et al. found the incidence of moderate to severe gastrointestinal and haematologic toxicities to be 24 and 11%, respectively, in dogs treated for lymphosarcoma. In a study of 133 dogs receiving doxorubicin as a 1-h infusion to treat a variety of different tumours, neutropenia occurred in 24 dogs (18%), gastrointestinal toxicity in 21 dogs (15.7%), sepsis in 3 dogs (2.2%), thrombocytopenia in 5 dogs (3.7%) and concurrent gastrointestinal toxicity and neutropenia in 7 dogs (5.2%).44 A dose-intensified doxorubicin protocol for haemangiosarcoma in 20 dogs found that 5 dogs had a Grade 1 neutropenia, 3 dogs had a Grade 2 neutropenia and 1 dog had a Grade 3 neutropenia. In this study of dose-intense doxorubicin reported by Sorenmo et al., five dogs required dose reductions because of neutropenia or gastroenteritis, while only one required a delay in treatment because of prolonged neutropenia.

In the present study, haematologic and gastrointestinal toxicities were mostly mild. Anaemia, neutropenia and thrombocytopenia were mostly classified as Grade 1 toxicity. Gastrointestinal toxicities occurred in 10 patients; however, six episodes of Grade 1 and three episodes of Grade 2 emesis were recorded and nine of the diarrhoea episodes noted were Grade 1. Thus, it appears that the addition
of dexrazoxane to doxorubicin in treatment of
tumour-bearing dogs did not appreciably increase
the incidence of common cytotoxic adverse effects.
It should be noted that toxic effects may be influ-
enced by dosing on lean body mass rather than total
body weight basis. In human patients, evaluation
of alternate size descriptors for dose calculation in
obese patients has limitations. The same may be
true for canine patients and prospective trials are
needed to address dosing chemotherapeutic drugs
based on body weight. Future prospective studies
need to be performed to compare incidence of gas-
trointestinal or other toxicities in dogs that received
1 mg/kg and 30 mg m² of doxorubicin to identify
any inherent sensitivities based on body weight.

There are several limitations of this study.
Chief among these are the small sample size and
retrospective nature of the study. In addition, only
14 dogs had serial echocardiograms to evaluate
for potential alterations of systolic function during
the course of therapy. Of these 14 dogs, only
7 had echocardiographic data that could be re-
evaluated by a single cardiologist to limit inter-
individual variability in calculation of the different
echocardiographic parameters. This unfortunate
circumstance was attributable to data retrieval
issues of the original echocardiographic unit when
a different manufacturer’s equipment was adopted
at MSU. Thus, while numerical measured values
were retrievable from the medical records of
these patients, the actual echocardiogram images
could not be recovered for re-assessment. One
of the dogs (English Terrier) with lost original
echocardiographic images developed clinical signs
of systolic dysfunction and evidence of mild
progressive heart disease (FS decreased from 20.2
to 18.8%). The second dog (Boxer) had improved
systolic function echocardiographically, but right
atrial enlargement on thoracic radiographs.

No information regarding efficacy of cardio-
protection can be gleaned from this work. In
human patients, the true incidence of cardiotox-
icity caused by doxorubicin is very low (~4%)
for patients who received 500–550 mg m². The
29.8% cardiotoxicity rate was reported in a cohort
of dogs treated with concurrent doxorubicin and
whole-body hyperthermia. The incidence of car-
diotoxicity in that study was similar between dogs
that received whole-body hyperthermia and those
that did not, suggesting that whole-body hyper-
thermia alone was not a significant contributor. In
that study onset of previously undetected arrhyth-
mia was considered a toxicity, which may have
contributed to the high reported incidence. Fur-
thermore, dogs had echocardiograms with every
treatment, which may have lead to a lower thresh-
old of detection of cardiac changes than in the
present work.

The low rate of possible cardiac toxicity noted
here is consistent with past reports, and in fact
is perhaps lower as the threshold for declaring
cardiac change was low in our study. Variance
in measurements and definitions of cardiotoxicity
thresholds between studies make direct comparison
difficult if not impossible. It is unclear whether
the administration of dexrazoxane had any role in
modulating the cardiac status of any of the cases in
this series, where therapy was discontinued because
of clinician’s concerns for progressive heart disease.
It is unfortunate that serial echocardiographic data
were not available on all dogs in this retrospective
study. Echocardiography is clearly helpful, along
with other markers of myocardial injury such
as serum levels of cardiac troponin, although
one might argue that echocardiography alone has
insufficient sensitivity to detect early myocardial
injury.

The present study was underpowered to evaluate
any cardioprotective effect in dogs without pre-
existing heart disease. For dogs treated with
doxorubicin, power analysis indicates that to detect
a 50% reduction in the incidence of cardiotoxicity
in tumour-bearing dogs with normal baseline
cardiac function (from 7.5 to 3.75% incidence),
with alpha of $P < 0.05$ and power of 80%, 589
dogs would be required for each of two groups,
comprising the dox/dex treatment arm and a
doxx-alone control arm. This analysis is based
on the assumption that all dogs would receive
180 mg m² cumulative doxorubicin dose, with no
animals withdrawn from the study because of
disease progression. In order to account for patient
attrition from progressive disease or unacceptable
non-cardiac toxicity, more dogs per groups should be recruited. Thus, while the efficacy of any cardioprotective effect of dexrazoxane in tumour-bearing dogs remains to be seen, the potential for such large prospective double-blinded trials is problematic because of issues of cost and practicality.

Similarly, it would be of questionable ethics to include a doxorubicin-alone control arm to a study of doxorubicin therapy in dogs with pre-existent heart disease, given that the cardioprotective effects of dexrazoxane in human patients are well established,\textsuperscript{10, 51} as it is in healthy beagle dogs used in dexrazoxane preclinical studies.\textsuperscript{33} It is difficult to calculate the numbers of dogs that would be required to statistically validate cardioprotective effects in breeds of historically increased cardiomyopathic risk, given the uncertainty of rate of cardiomyopathy induction in such breeds treated with doxorubicin alone. In one study of dogs given doxorubicin at 30 mg m\textsuperscript{2} every 2 weeks for treatment of osteosarcoma, close to 50\% of Doberman Pinschers (6 of 13) and Great Danes (3 of 7) in the study developed clinical cardiotoxicity.\textsuperscript{48} A power analysis suggests that to reduce the rate of cardiotoxicity in patients of these three breeds from 50 to 25\%, with alpha of $P < 0.05$ and power of 80\%, 55 dogs in each of the doxorubicin and dox/dex groups would be required. A large-scale controlled prospective trial involving specific breeds of dogs may be invaluable in identifying those dogs at risk for cardiotoxicity (high-risk breeds) as well as others that may not traditionally be considered at risk. The potential benefit of dexrazoxane would be best assessed in such an at-risk cohort of dogs.

Based on human and veterinary clinical observations, it is possible that dogs with subclinical cardiomyopathies might benefit from dexrazoxane. In human medicine, additional markers to detect patients at higher risk of developing cardiotoxicity because of doxorubicin have been evaluated. Brain natriuretic peptide and troponin T levels, for example, have been studied as biomarkers of cardiotoxicity in rats,\textsuperscript{52} and it appears that patients at higher risk for developing cardiotoxicity may be identified before any echocardiographic changes are noted.\textsuperscript{51} Selting et al.\textsuperscript{55} evaluated cardiac troponin I levels in dogs treated with doxorubicin for lymphoma and osteosarcoma. These investigators documented that cardiac troponin I levels were increased in advance of cardiac changes detectable either clinically or by post-treatment echocardiogram. Detection of subclinical cardiac damage through serum biomarkers may allow early application of dexrazoxane as a cardioprotectant in individual dogs at increased risk of doxorubicin cardiotoxicity. Moreover, endomyocardial biopsy is considered the ‘gold standard’ for detection of heart damage induced by anthracyclines. This invasive approach may not prove feasible or practical in a clinical setting. If risk of doxorubicin administration precludes its use, alternative chemotherapeutic drugs such as epirubicin or mitoxantrone may be used or changing to a different class of agents can be considered. Alterations in administration of doxorubicin may be another possible way of avoiding potential toxicity, such as administering doxorubicin as a constant rate infusion to reduce peak plasma concentrations.\textsuperscript{44}

Ideally, in future studies, a doxorubicin-treated control group of breed- and age-matched dogs should be included to prospectively evaluate any cardiac benefit of dexrazoxane administered in conjunction with doxorubicin. Based on our assessment of the patient numbers required to complete such an effort, a multicenter trial with sufficient funding support would be necessary. Additional prospective studies may also address the ability of dexrazoxane administration to facilitate increase in doxorubicin dose or cumulative threshold escalation. Pharmacokinetic data of doxorubicin are also needed to identify kinetic changes that are noted with dox/dex administration which could affect potential toxicity, therapeutic efficacy and treatment protocol design. Dogs represent important translational pharmacokinetic and biologic models of drugs for human patients, based on similarities in pharmacokinetic parameters such as half-life, volume of distribution, metabolism and elimination. Because cardiomyopathic change is associated with doxorubicin administration to dogs in both investigational and clinical settings, it is reasonable to model cardioprotectant drugs in this species as well.\textsuperscript{31, 44, 49} Other iron chelators and novel therapeutic drugs may be used in a clinical setting.
to ameliorate the cardiotoxicity of doxorubicin. In children treated with doxorubicin for various malignancies, the incidence of long-term medical problems such as heart disease and second malignancies may not be seen for months or even many years later. The application of cardioprotectant drugs such as dexrazoxane has been shown to be beneficial in human cancer patients and this is likely the case in dogs.

From the present study, it appears that one to two doses of dexrazoxane administered with doxorubicin are safe and well tolerated under the protocol parameters used here.

Acknowledgments

We would like to thank the oncology and cardiology technicians, and fellow oncology residents of MSU’s Animal Cancer Care Clinic. Additional appreciation is given to Paul Curran at the MSU Center for Statistical Training and Consulting, and Robert Sanders, DVM, DACVIM (Cardiology) for evaluation of echocardiographic data. We have no conflicts of interest to report.

References


35. Sehsted M, Jensen PB, Sorensen BS, Holm B, Friche E and Demant EJ. Antagonistic effect of the cardioprotector (+)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane (ICRF-187) on DNA breaks and cytotoxicity induced by the topoisomerase II directed drugs daunorubicin and etoposide (VP-16). Biochemical Pharmacology 1993; 46: 389–393.


42. Vail, DM. Veterinary Co-operative Oncology Group – common terminology criteria for adverse events (VCOG-CTCAE) following chemotherapy or biological antineoplastic therapy in dogs and cats v1.0. Journal of Veterinary and Comparative Oncology 2004; 2: 194–213.


